Intravenous immunoglobulin, or IVIG, is a cornerstone therapy for individuals with primary immunodeficiencies, certain autoimmune conditions, and a growing list of neuroinflammatory disorders. While often perceived as a straightforward pass of antibodies, the infusion carries a spectrum of potential risks that demand careful consideration and vigilant monitoring. Understanding these risks in detail empowers patients and clinicians to make informed decisions and mitigate complications before they escalate.
Common and Generally Manageable Side Effects
The majority of adverse events linked to IVIG are mild and transient, occurring during or shortly after the infusion. These reactions are often the body’s response to the foreign proteins and the rate at which they are introduced into the bloodstream. Most clinics are equipped to handle these immediate effects effectively, allowing the treatment to continue safely with adjustments.
Headache and myalgia, often resembling a mild flu-like syndrome.
Nausea, flushing, or a sensation of warmth during the infusion.
Hypotension or mild tachycardia as the body adjusts to the volume and composition.
Infusion-Related Reactions and Rate Management
A significant subset of side effects stems from the speed of administration. The body can react negatively if the antibodies are delivered too quickly, placing stress on the vascular system. Modern protocols emphasize slow, controlled infusion rates, particularly during the initial phases of treatment.
The Role of Pre-Medication
Clinicians frequently utilize pre-medication to blunt the intensity of these reactions. Standard regimens may include acetaminophen or antihistamines like diphenhydramine. In specific cases where headaches are severe, a trial of corticosteroids might be considered to reduce inflammation and discomfort associated with high-volume infusions.
Renal Impairment and Hydration Concerns
One of the more serious risks associated with high-dose IVIG therapy is its potential to impact kidney function. The concentrated sugar solutions and the sheer volume of fluid can place a burden on the kidneys, leading to a condition known as acute kidney injury or renal failure. This risk is notably elevated in patients with pre-existing renal conditions or those taking nephrotoxic medications.
Hydration is the primary defense against this complication. Aggressive intravenous fluid administration before, during, and after the infusion helps to flush the kidneys and dilute the immunoglobulin load. Monitoring urine output and serum creatinine levels is a standard practice in high-risk scenarios.
Thromboembolic Events and Hypercoagulability
IVIG carries a subtle but significant risk of promoting blood clots. The mechanism is complex but involves the activation of platelets and the elevation of blood viscosity. This hypercoagulable state can lead to deep vein thrombosis (DVT), pulmonary embolism (PE), or, more rarely, stroke or myocardial infarction.
Patients with a history of thrombotic events, those who are immobilized, or individuals with underlying clotting disorders are generally approached with caution. The balance between the therapeutic benefit of the immunoglobulin and the risk of vascular occlusion is a critical calculation for the prescribing physician.
Hematologic and Laboratory Disturbances
Beyond the kidneys and vascular system, IVIG can cause transient shifts in the body’s blood composition. One notable effect is hemolysis, where the donor antibodies inadvertently recognize and destroy the recipient’s red blood cells. This results in a drop in hemoglobin and can cause jaundice or dark urine.
Additionally, patients may experience a temporary rise in blood viscosity, which can interfere with accurate laboratory results. Labs often recommend that samples be drawn from a different vein or that specific tests be delayed to avoid misleading interpretations based on hemolyzed or hyperviscous samples.
